Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Estudio abierto, de múltiples brazos de tratamiento, no comparativo para evaluar la seguridad y tolerabilidad de canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica (AIJS) activa.]

Next Previous
Trial Profile

An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Estudio abierto, de múltiples brazos de tratamiento, no comparativo para evaluar la seguridad y tolerabilidad de canakinumab (ACZ885) en pacientes con artritis idiopática juvenil sistémica (AIJS) activa.]

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational
  • Acronyms Beta-SPECIFIC-4Pa
  • Sponsors Novartis

Most Recent Events

  • 02 Feb 2013 Planned number of patients changed from 220 to 239 as reported by European Clinical Trials Database record.
  • 02 Feb 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-003054-92).
  • 24 Jan 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top